Rat Pharmacokinetics and PBK Model for a Perfluoroalkyl Substance

Experimental data characterizes the absorption and disposition kinetics of Bis[2-(perfluorohexyl)ethyl] phosphate (6:2 diPAP) in rats, including intravenous and oral dosing results under fed and fasted conditions. The dataset supports a physiologically-based kinetic model used for human exposure estimation. Minsang Kim authored this study, which was last updated in April 2026.

Use Cases

• Model plasma concentration-time profiles using intravenous and oral dosing data from fed and fasted rats.
• Estimate human external exposure levels via reverse dosimetry using the provided physiologically-based kinetic model parameters.
• Analyze elimination pathways by comparing renal clearance data with biliary excretion rates (14.5% of intravenous dose).
• Assess food effect on systemic exposure by comparing bioavailability and clearance metrics between fed and fasted animal groups.
• Validate hepatic clearance estimates (75.3 mL/h/kg in rats) against intrinsic clearance data from liver S9 fractions and biliary excretion.

Strengths

• Includes specific pharmacokinetic parameters such as a half-life of 32.1 ± 4.3 hours and clearance of 86.2 ± 20.8 mL/h/kg from intravenous dosing.
• Integrates multiple data sources: in vivo rat experiments, in vitro assays, and in silico modeling for a mechanistic understanding.
• Model validation against plasma concentration-time profiles for both fed and fasted experimental conditions.

Limitations

• Dataset is small (2.0 MB), likely containing summary model parameters and results rather than raw experimental time-series data.
• Findings are specific to a single chemical (6:2 diPAP) and a rat model, limiting direct generalizability to other substances or humans without extrapolation.
• Temporal coverage of the underlying experimental data is not specified, though the model was updated in 2026.

Provenance

Source

Minsang Kim, via figshare.

Collection Method

Data generated from in vivo rat experiments (intravenous and oral dosing) and in vitro assays (liver S9 fractions), integrated into a physiologically-based kinetic model.

Freshness

Last updated in April 2026.